Pre Quotation Disclosure

Melbourne, AU and Dallas, US – 27 November 2025

The following information is required to be provided to ASX Limited (**ASX**) for release to the market in connection with the admission to the Official List of ASX and official quotation of fully paid ordinary shares in Epiminder Limited (ACN 616 831 684) (**Epiminder**).

Capitalised terms which have not been otherwise defined in this document have the meaning given to them in the replacement prospectus lodged by Epiminder with the Australian Securities and Investments Commission on 10 November 2025 (**Prospectus**).

1. Capital structure

The table below sets out Epiminder's current capital structure.

Type of security	Number of securities
Shares	216,671,652
Options	15,493,080

2. Results of the Offer

The Company confirms that it has raised $125 million under the Offer via the issuance of 83,333,332 New Shares at $1.50 per New Share.

The total number of New Shares allocated under each part of the Offer is:

Offer Category	Number of New Shares
Institutional Offer	59,910,145
Broker Firm Offer	22,565,243
Priority Offer	857,944
Total	**83,333,332**

3. Manufacturing Shares

Epiminder confirms that it has issued 16,000,000 Shares to Cochlear Investments under the terms of the Collaboration Agreement. Refer to Section 10.8 of the Prospectus for further information.

4. Options

Epiminder confirms that it has issued 7,780,856 Options, exercisable at $1.50 each and expiring on 27 November 2040 under the terms of its LTI Plan. Refer to Section 6.5.2 of the Prospectus for further information.

5. Despatch date

The date for the despatch of:

(a) in relation to all holdings on the CHESS sub-register, a notice from Epiminder under ASX Settlement Operating Rule 8.9.1;

(b) in relation to all other holdings, issuer sponsored holding statements; and

(c) any refund money,

is 27 November 2025.

6. Mandatory escrow

Epiminder confirms that, subject to official quotation on ASX, the following securities will be subject to mandatory escrow restrictions under the ASX Listing Rules:

Class of securities	Number of securities	Mandatory escrow period
Shares (Cochlear Investments)	38,845,550 Shares	24 months from Listing
Shares (Directors and their related entities)	1,547,634 Shares	24 months from Listing
Shares (Other promoters)	775,366 Shares	24 months from Listing
Shares (Pre-IPO Noteholders, other than Cochlear Investments)	316,806 Shares	12 months from the issue date of the Pre-IPO Notes (c. March – April 2026)
Options	8,665,864 Options	24 months from Listing
Total	**41,485,356 Shares** **8,665,864 Options**	

7. Voluntary escrow

Epiminder confirms that, subject to official quotation on ASX, the following securities will be subject to voluntary escrow restrictions imposed under a voluntary escrow deed between the relevant holder and Epiminder:

Holder	Number and class of securities	Voluntary escrow period
Cochlear Investments	71,315,403 Shares	Three years from Listing
The Bionics Institute of Australia	15,773,644 Shares	Three years from Listing
St Vincent's Hospital (Melbourne)	7,821,432 Shares	Three years from Listing
University of Melbourne	7,543,140 Shares	Three years from Listing
Directors and their related entities	699,844 Shares	24 months from Listing

Other promoters	469,099 Shares	24 months from Listing
Total	**103,622,562 Shares**	

Epiminder notes that 1,168,943 Shares held by directors, promoters and their related parties are now subject to voluntary escrow arrangements for a period of 24 months from Listing. It was expected that these Shares were going to be subject to mandatory escrow imposed by ASX for the same period. However, ASX has since confirmed that cash formula relief is available to those holders.

Accordingly, to ensure that Epiminder's free float at Listing is the same as disclosed in the Prospectus, the Shares held by those related parties, promoters and related entities which are not subject to ASX-imposed mandatory escrow are now subject to voluntary escrow. As a result, the overall escrow period for related parties, promoters and their related parties remains unchanged to that disclosed in the Prospectus.

While a lesser number of Shares held by Cochlear Investments is subject to mandatory escrow (as a result of the availability of cash formula relief), the entirety of Cochlear Investments' holding (other than the New Shares acquired under the Offer) is already subject to voluntary escrow for a period of three years from Listing.

8. Relevant Interest

As a result of the updated voluntary escrow arrangements, Epiminder will have a relevant interest in approximately 47.8% of the Shares on issue on Listing.

9. Further information

The following documents will be released on the ASX Market Announcements Platform at the same time as this pre-quotation disclosure:

i. Epiminder's Appendix 1A and Information Form and Checklist;
ii. The Prospectus dated 10 November 2025;
iii. Epiminder's constitution;
iv. Epiminder's audited financial statements for the full years ending 30 June 2024 and 30 June 2025;
v. The full terms and conditions of Epiminder's LTI Plan;
vi. Epiminder's corporate governance statement which discloses the extent to which Epiminder will follow, as at the date of its admission to the Official List, the recommendations set by the ASX Corporate Governance Council;
vii. Epiminder's securities trading policy;
viii. A distribution schedule of the number of holders in each class of securities to be quoted, setting out the number and percentage of holdings in the following categories:
    - 1 – 1,000
    - 1,001 – 5,000
    - 5,001 – 10,000
    - 10,001 – 100,000
    - 100,001 and over

ix. A statement setting out the names of the 20 largest holders of each class of securities to be quoted, including the number and percentage of each class of securities held by those holders.

If there are any queries please contact Epiminder at investors@epiminder.com

Authorised for release by Board of Directors.

END

+++

Follow Epiminder on LinkedIn and explore Epiminder.com for more information.

About Minder

Minder is a minimally invasive device for continuous monitoring of electrographic activity of the brain, providing epilepsy patients and their doctors with detailed data on brain activity over an extended period. Patients can wear the device as they go about their normal daily activities.

Minder's long-term monitoring of patients outside a controlled clinical environment provides clinicians with the data needed to remotely monitor and assess the patient's underlying condition, including the effectiveness of drug therapies and other interventions.

About Epiminder

Founded in 2017 by Professor Mark Cook together with the Bionics Institute, St Vincent's Hospital, the University of Melbourne and Cochlear Limited, Epiminder is a medical device and information solutions company focused on developing diagnostic and treatment tools for epilepsy and other seizure disorders where continuous monitoring is required. Epiminder is headquartered in Melbourne, Australia and has offices in the United States.